{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin+10+mg+Tablet&page=2", "query": { "intervention": "Rosuvastatin 10 mg Tablet", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 31, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin+10+mg+Tablet&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosuvastatin+10+mg+Tablet&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T21:19:00.574Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01953835", "title": "A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "GSK2586184 standard formulation", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "GSK2586184 new formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2013-10-04", "completion_date": "2014-03-10", "has_results": false, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01953835" }, { "nct_id": "NCT04542382", "title": "Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Rosuvastatin (Inhibitor arm)", "type": "DRUG" }, { "name": "Eltrombopag", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 11, "start_date": "2021-10-28", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04542382" }, { "nct_id": "NCT01489943", "title": "A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "GSK1605786 500 mg", "type": "DRUG" }, { "name": "Midazolam 3 mg", "type": "DRUG" }, { "name": "Pioglitazone 15 mg", "type": "DRUG" }, { "name": "Omeprazole 40 mg", "type": "DRUG" }, { "name": "Rosuvastatin 10 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2011-09-19", "completion_date": "2011-11-10", "has_results": false, "last_update_posted_date": "2017-07-25", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01489943" }, { "nct_id": "NCT01644188", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for ezetimibe)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 720, "start_date": "2012-08", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644188" }, { "nct_id": "NCT02082665", "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Rosuvastatin10 mg tablet", "type": "DRUG" }, { "name": "Midazolam 3 mg syrup", "type": "DRUG" }, { "name": "Dabrafenib 75 mg capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2015-02-19", "completion_date": "2016-08-01", "has_results": false, "last_update_posted_date": "2017-07-24", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082665" }, { "nct_id": "NCT06742853", "title": "A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dyslipidemia" ], "interventions": [ { "name": "AZD0780", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Bempedoic Acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 81, "start_date": "2024-12-20", "completion_date": "2025-10-29", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06742853" }, { "nct_id": "NCT07372625", "title": "A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "TP53 Y220C Mutation", "Advanced Solid Tumors" ], "interventions": [ { "name": "metformin hydrochloride 500 mg tablet", "type": "DRUG" }, { "name": "rosuvastatin 10 mg tablet", "type": "DRUG" }, { "name": "repaglinide 0.5 mg tablet", "type": "DRUG" }, { "name": "midazolam hydrochloride syrup", "type": "DRUG" }, { "name": "rezatapopt", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-02-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 5, "location_summary": "Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07372625" }, { "nct_id": "NCT06186622", "title": "A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy", "Obese", "Overweight" ], "interventions": [ { "name": "Orforglipron", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Sodium Bicarbonate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2024-01-02", "completion_date": "2024-07-10", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06186622" }, { "nct_id": "NCT01763866", "title": "LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "BIOLOGICAL" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo to Evolocumab", "type": "DRUG" }, { "name": "Placebo to Ezetimibe", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2067, "start_date": "2013-01-15", "completion_date": "2013-12-04", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01763866" }, { "nct_id": "NCT07838987", "title": "A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "TERN-701", "type": "DRUG" }, { "name": "Rabeprazole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Bosentan", "type": "DRUG" }, { "name": "Quinidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 196, "start_date": "2023-12-21", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-06T21:19:00.574Z", "location_count": 1, "location_summary": "Millcreek, Utah", "locations": [ { "city": "Millcreek", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07838987" } ] }